BURLINGTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics today announced that Kerry Wentworth, Chief Regulatory Officer, has been appointed to the Massachusetts Biotechnology Council (MassBio) Board of Directors. Flexion Therapeutics today announced that Kerry Wentworth, Chief
BURLINGTON, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman , M.D., President and Chief Executive Officer, will present at the Cowen 39 th Annual Health Care Conference in Boston, Massachusetts . Dr.
BURLINGTON, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to five new employees for an aggregate of 19,250 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with
Company reported net ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) sales of $22.5 million for full-year 2018 Since launch, 90% of target accounts have purchased or received samples of ZILRETTA and 69% of ordering accounts have placed reorders Company received Day 74
BURLINGTON, Mass. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be presenting at the 40 th Annual Raymond James Institutional Investors Conference in Orlando, Florida . Michael Clayman , M.D., President and Chief Executive Officer, is
Study conducted in collaboration with MIT showed that triamcinolone acetonide had protective effects on inflamed and/or injured cartilage in an established preclinical model Data presented in “late breaker” session at the recent 2019 Orthopaedic Research Society Annual Meeting BURLINGTON, Mass.
BURLINGTON, Mass. , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Thursday, February 28, 2019 .
Results from Phase 3b clinical trial indicate that repeat administration of ZILRETTA for osteoarthritis (OA) knee pain was generally safe and well-tolerated X-ray data at baseline and Week 52 showed ZILRETTA had no deleterious impact on cartilage or joint structure The majority (74%) of
BURLINGTON, Mass. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019 to commemorate the fifth anniversary of the company’s initial public offering (IPO).
BURLINGTON, Mass. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants with an
